Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
[Preprint]. 2024 Feb 6:2024.02.05.24302343.
doi: 10.1101/2024.02.05.24302343.

TNF promoter hypomethylation is associated with mucosal inflammation in IBD and anti-TNF response

Affiliations

TNF promoter hypomethylation is associated with mucosal inflammation in IBD and anti-TNF response

Daniel S Levic et al. medRxiv. .

Update in

  • TNF Promoter Hypomethylation Is Associated With Mucosal Inflammation in IBD and Anti-TNF Response.
    Levic DS, Niedzwiecki D, Kandakatla A, Karlovich NS, Juneja A, Park J, Stolarchuk C, Adams S, Willer JR, Schaner MR, Lian G, Beasley C, Marjoram L, Flynn AD, Valentine JF, Onken JE, Sheikh SZ, Davis EE, Evason KJ, Garman KS, Bagnat M. Levic DS, et al. Gastro Hep Adv. 2024 Jun 27;3(7):888-898. doi: 10.1016/j.gastha.2024.06.010. eCollection 2024. Gastro Hep Adv. 2024. PMID: 39286616 Free PMC article.

Abstract

Background and aims: Inflammatory Bowel Diseases (IBD) are chronic inflammatory conditions influenced heavily by environmental factors. DNA methylation is a form of epigenetic regulation linking environmental stimuli to gene expression changes and inflammation. Here, we investigated how DNA methylation of the TNF promoter differs between inflamed and uninflamed mucosa of IBD patients, including anti-TNF responders and non-responders.

Methods: We obtained mucosal biopsies from 200 participants (133 IBD and 67 controls) and analyzed TNF promoter methylation using bisulfite sequencing, comparing inflamed with uninflamed segments, in addition to paired inflamed/uninflamed samples from individual patients. We conducted similar analyses on purified intestinal epithelial cells from bowel resections. We also compared TNF methylation levels of inflamed and uninflamed mucosa from a separate cohort of 15 anti-TNF responders and 17 non-responders. Finally, we sequenced DNA methyltransferase genes to identify rare variants in IBD patients and functionally tested them using rescue experiments in a zebrafish genetic model of DNA methylation deficiency.

Results: TNF promoter methylation levels were decreased in inflamed mucosa of IBD patients and correlated with disease severity. Isolated IECs from inflamed tissue showed proportional decreases in TNF methylation. Anti-TNF non-responders showed lower levels of TNF methylation than responders in uninflamed mucosa. Our sequencing analysis revealed two missense variants in DNMT1, one of which had reduced function in vivo.

Conclusions: Our study reveals an association of TNF promoter hypomethylation with mucosal inflammation, suggesting that IBD patients may be particularly sensitive to inflammatory environmental insults affecting DNA methylation. Together, our analyses indicate that TNF promoter methylation analysis may aid in the characterization of IBD status and evaluation of anti-TNF therapy response.

Keywords: Anit-TNF Response; Epigenetics; Inflammatory Bowel Disease; Methylation.

PubMed Disclaimer

Conflict of interest statement

Disclosures The authors have no conflicts of interest to disclose.

Figures

Figure 1.
Figure 1.. Methylation analysis of the TNF promoter from healthy human colon mucosa.
(A) Schematic of the human TNF gene. CpG sites of the promoter region (red line) are shown in the boxed inset. (B) Methylation analysis of the TNF promoter from healthy human colon using targeted bisulfite sequencing. Columns represent individual CpG sites, and rows are 10 sequencing replicates for a single donor. Filled circles are methylated CpG sites, while open circles are non-methylated. (C) Quantification of methylation analysis from healthy human colon. Individual data points are average methylation values from n=6 individual donors. Mean ± SD are plotted. P value was calculated using a non-parametric Wilcoxon two sample test.
Figure 2.
Figure 2.. Inflamed mucosa of IBD cases exhibit TNF hypomethylation.
(A) Methylation analysis of the TNF promoter from mucosa of controls (n=67 donors; 69 samples) and IBD cases (n=133 donors; 199 samples). (B) IBD cases were stratified according to biopsy inflammation status. (C) IBD cases were stratified according to disease subtype and biopsy inflammation status. (D) Methylation analysis of an independent cohort of IBD cases (n=15 donors; 26 samples) obtained from a separate study site. Data points are average methylation values for individual biopsies. Mean ± SD are plotted. P values were calculated using non-parametric Wilcoxon two sample tests (A, B, D) or a non-parametric Kruskal-Wallis H test (C).
Figure 3.
Figure 3.. Association of TNF hypomethylation with mucosal inflammation.
(A) TNF Methylation analysis of IBD cases stratified by local mucosal disease activity. Categories: 1, uninflamed biopsies from IBD patients without active disease; 2, uninflamed biopsies from IBD patients with active disease; 3, inflamed biopsies from IBD patients exhibiting mild or focal inflammation; 4, inflamed biopsies from IBD patients exhibiting chronic or acute colitis. Data points are average methylation values for individual biopsies. Mean ± SD are plotted. (B) TNF Methylation analysis of paired uninflamed and inflamed mucosal samples from individual IBD cases (n=58 donors). Connecting lines indicate paired samples. P values were calculated using non-parametric Kruskal-Wallis (A) or Wilcoxon matched-pairs signed rank tests (B).
Figure 4.
Figure 4.. Anti-TNF non-responders have lower levels of TNF methylation than responders.
(A-B) TNF Methylation analysis of anti-TNF responders and non-responders in uninflamed (A) or inflamed (B) mucosa. Data points are average methylation values from individual cases. Mean ± SD are plotted. P values were calculated using parametric unpaired t tests.
Figure 5.
Figure 5.. TNF hypomethylation of IECs is associated with inflammation and increased IEC tnf expression.
(A) TNF Methylation analysis of FACS isolated IECs obtained from bowel resections of non-IBD (NIBD) controls and inflamed CD cases. Data points are average methylation values from individual cases and controls. Mean ± SD are plotted. (B-C) 1-cell stage dnmt1s872 zebrafish mutants and WT siblings expressing TgBAC(tnfa:GFP)pd1028 as an inflammation reporter were injected with transgenic constructs to mosaically express human DNMT1-p2A-RFP specifically in IECs. At 5 days post fertilization (dpf), transverse sections of the intestine were collected and imaged by confocal microscopy. Arrows point to sparsely labeled RFP+ cells expressing DNMT1 in dnmt1s872 mutants. Scale bars are 50 μm. (D) Quantification of tnfa:GFP expression in dnmt1s872 mutants. N=217 (RFP-) and 57 (RFP+) IECs from 10 larvae. Mean ± SD are plotted. (E) Quantification of tnfa:GFP expression in dnmt1s872 mutants from paired RFP− and RFP+ IECs from individual tissue sections. N=10 larvae. P values were calculated using non-parametric Wilcoxon two sample tests (A, D) or a Wilcoxon matched-pairs signed rank tests (E).
Figure 6.
Figure 6.. Functional analysis of rare DNMT1 variants in a zebrafish dnmt1 mutant model.
(A-E) Live confocal imaging of TgBAC(tnfa:GFP) in 5 dpf dnmt1s872 mutant larvae and WT siblings. 1-cell stage embryos were injected with cRNA encoding WT or variant DNMT1, raised to 5 dpf, imaged, and then genotyped. Dotted line demarcates the anterior intestinal epithelium. Right panels show GFP overlayed with brightfield images. Scale bars are 200 μm. (F) Quantification of tnfa:GFP intensity in the anterior intestinal epithelium from experiments in panels A-E. Mean ± SD are plotted. P values were calculated using two-way ANOVA. Data points are mean pixel intensity values from individual larvae.

References

    1. Jostins L, Ripke S, Weersma RK, et al. Host-microbe interactions have shaped the genetic architecture of inflammatory bowel disease. Nature 2012;491:119–24. - PMC - PubMed
    1. Liu JZ, van Sommeren S, Huang H, et al. Association analyses identify 38 susceptibility loci for inflammatory bowel disease and highlight shared genetic risk across populations. Nat Genet 2015;47:979–986. - PMC - PubMed
    1. de Lange KM, Moutsianas L, Lee JC, et al. Genome-wide association study implicates immune activation of multiple integrin genes in inflammatory bowel disease. Nat Genet 2017;49:256–261. - PMC - PubMed
    1. Neurath MF. Cytokines in inflammatory bowel disease. Nat Rev Immunol 2014;14:329–42. - PubMed
    1. D’Haens GR, van Deventer S. 25 years of anti-TNF treatment for inflammatory bowel disease: lessons from the past and a look to the future. Gut 2021;70:1396–1405. - PubMed

Publication types